Tech Company Financing Transactions
Peroxitech Therapeutics Funding Round
Peroxitech Therapeutics, based in Philadelphia, secured investment capital from Xontogeny.
Transaction Overview
Company Name
Announced On
5/13/2021
Transaction Type
Venture Equity
Amount
Unknown
Round
Seed
Investors
Xontogeny (Chris Garabedian)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3401 Grays Ferry Ave. Building 212 153
Philadelphia, PA 19146
USA
Philadelphia, PA 19146
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Peroxitech is a biotech start-up out of the University of Pennsylvania. Our lead program is a breakthrough treatment for acute lung injury. The most pressing indication for our lead candidate is COVID-19 induced acute lung injury. In these patients, acute lung injury is the leading cause of death. Our co-founders and scientists discovered a new pathway and a novel drug to treat and prevent acute lung injury.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Thomas Han
Co-Founder
Sheldon Feinstein
Co-Founder
Aron Fisher
Browse more venture capital transactions:
Prev: 5/13/2021: CircleCI venture capital transaction
Next: 5/13/2021: Treasury Prime venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs